Billing and Coding: MolDX: Immunohistochemistry (IHC) Indications for Breast Pathology
A54271
Based on recommendations from the College of American Pathologists, the American Society of Clinical Oncologists (ASCO), and the National Comprehensive Cancer Network (NCCN), hormone receptor assays, estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu are the only current biomarkers that demonstrate standardized value in breast cancer pathology evaluation. Although other biomarkers, such as Ki-67, PI3K, and gene expression assays, have been studied, no proven standardized value has been established. Therefore, CGS Administrators and the MolDX program contractor will allow ER, PR, and Her2 testing by IHC for patients with primary invasive breast cancers and recurrent or metastatic cancers.To report an IHC service for an ER, PR, Her2, submit the following claim information: CPT® Code Specimen UOS 88342 First single/multiplex stain 1 88341 Each additional 2 To report morphometric analysis, select one of the following codes based on the type of morphometric analysis: CPT® Code Service Type UOS 88360 Manual 3 88361 Computer-assisted 3 <p style="box-sizing: border-box; color: #333333; font-family: Verdana," helvetica neue",helvetica,arial,sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; o